An Inactivated Cell-Culture Vaccine against Yellow FeverArchived
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, july 2017 to March 2018
Gossner, C.M., Haussig, J.M., de Bellegarde de Saint Lary, C., Kaasik Aaslav, K., Schlagenhauf, P., Sudre, B.